๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 451 Beijing 25 Shenzhen 23 Zhongshan 17 Nanning 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81 Clear sponsor filter
Site location
Guangzhou451 Beijing25 Shenzhen23 Zhongshan17 Nanning17
All 55 locations
Target enrolment
to

Trials with a site in Guangzhou

451 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
NCT06829147Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2024-11-19
Recruiting
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
NCT06624696Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events, Anticholinergics, Inhalation Therapy; Complications
Sun Yat-sen University
Phase 4
204
Guangzhou, Shenzhen
2024-11-12
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NCT06742502Primary Mediastinal Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2
30
Fuzhou, Guangzhou
2024-11-12
Recruiting
Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy
NCT07043491Esophageal Cancer, Surgery-Complications
Sun Yat-sen University
Observational
2
Guangzhou
2024-11-04
Not yet open
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
NCT06684873NSCLC, Brain Metastasases
Sun Yat-sen University
Phase 2
55
Guangzhou
2024-11-02
Recruiting
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
NCT06563999Lung Cancer Stage III, Mutation
Sun Yat-sen University
Phase 2
120
Guangzhou
2024-11-01
Recruiting
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
NCT06520683Colorectal Cancer, Microsatellite Instability High
Sun Yat-sen University
Phase 3
180
Guangzhou
2024-11-01
Recruiting
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study
NCT06848582Soft Tissue Sarcoma (STS)
Sun Yat-sen University
Not applicable
40
Guangzhou, Dongguan
2024-11-01
Recruiting
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
NCT06631391Neuroblastoma
Sun Yat-sen University
Phase 1
30
Guangzhou
2024-11-01
Recruiting
Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease
NCT06579326Lower Extremity, Photoacoustic
Sun Yat-sen University
Observational
200
Guangzhou
2024-11-01
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Active, closed
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
NCT06647732Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sun Yat-sen University
Phase 2
42
Guangzhou
2024-10-30
Recruiting
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
NCT06848569Classical Hodgkin Lymphoma
Sun Yat-sen University
Phase 2
73
Guangzhou
2024-10-23
Recruiting
Arsenous Acid for Refractory Triple-Negative Breast Cancer
NCT06678048Breast Cancer
Sun Yat-sen University
Phase 2
12
Guangzhou
2024-10-23
Recruiting
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
NCT06583083Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sun Yat-sen University
Phase 2
84
Guangzhou
2024-10-22
Active, closed
TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06664983Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
84
Guangzhou
2024-10-21
By invitation
Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Colorectal Cancer Surgery
NCT06636864Laparoscopic Colorectal Cancer Surgery
Sun Yat-sen University
Not applicable
252
Guangzhou
2024-10-15
Recruiting
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09-26
Recruiting
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
NCT06492460Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Recruiting
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
NCT06611137Laryngeal Cancer, Hypopharynx Cancer
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-09-11
Recruiting
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
NCT07648069Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 1
16
Guangzhou
2024-09-03
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
NCT06588764Graves Ophthalmopathy, Surgery
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09
Recruiting
Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer
NCT06485609Colon Cancer
Sun Yat-sen University
Not applicable
1,200
Guangzhou
2024-08-10
Recruiting
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
NCT06611150Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 1
24
Guangzhou
2024-08-02
Recruiting
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
NCT06545747Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
NCT06517511Diffuse Large B Cell Lymphoma
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
NCT06529549Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University
Observational
30
Guangzhou
2024-07-24
Active, closed
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-07-23
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
NCT06547203Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
Sun Yat-sen University
Phase 2
23
Guangzhou
2024-07-17
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
NCT06323239Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
GOS and the Management of Hyperuricemia
NCT06630377Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
70
Guangzhou
2024-07-15
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
NCT06456892Rhabdomyosarcoma, Pediatric Cancer
Sun Yat-sen University
Phase 1/2
82
Guangzhou
2024-06-06
Recruiting
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
NCT06415318Penile Cancer
Sun Yat-sen University
Phase 2
25
Guangzhou
2024-05-31
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
NCT06441565Colorectal Cancer
Sun Yat-sen University
Phase 2/3
84
Guangzhou
2024-05-24
Recruiting
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
NCT06569485DLBCL
Sun Yat-sen University
Phase 2
38
Guangzhou
2024-05-23
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Recruiting
Prebiotics and the Management of Hyperuricemia
NCT06420401Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
160
Guangzhou
2024-05-15
By invitation
A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer
NCT06396806Sigmoid Cancer
Sun Yat-sen University
Not applicable
1,072
Guangzhou
2024-05-06
Not yet open
KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
NCT06370026Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase EARLY_PHASE1
12
Guangzhou
2024-05-01
Recruiting
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
Sun Yat-sen University
Observational
200
Guangzhou, Shenzhen
2024-04-24
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
NCT06313190Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Recruiting
Factors Associated With Posttransplant Cardiac Outcomes
NCT06290154Cardiovascular Diseases, Liver Transplantation
Sun Yat-sen University
Observational
200
Guangzhou
2024-04-01
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
NCT06313450Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Active, closed
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
NCT06143748Esophagus Cancer
Sun Yat-sen University
Phase 2
46
Guangzhou
2024-03-02
Not yet open
Myeloprotection With Trilaciclib in Pan-cancer Population
NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
Sun Yat-sen University
Phase 2
132
Guangzhou
2024-03-01
Recruiting
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
NCT06187597Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-03-01
Recruiting
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
NCT06582940MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
Sun Yat-sen University
Phase 2
168
Guangzhou
2024-03-01
Not yet open
Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)
NCT06227286Mitral Regurgitation
Sun Yat-sen University
Not applicable
176
Guangzhou, Jieyang, Shantou, Zhongshan
2024-03-01
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
NCT07583511Small-cell Lung Cancer
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
Recruiting
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
NCT06280495Colorectal Cancer, Liver Metastases
Sun Yat-sen University
Phase 2/3
156
Guangzhou
2024-02-01
Recruiting
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
NCT06241599Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2/3
300
Guangzhou
2024-02-01
Not yet open
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
NCT06054191NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
NCT06733051Natural Killer T-cell Lymphoma
Sun Yat-sen University
Phase 2
47
Beijing, Guangzhou
2024-01-27
Recruiting
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
NCT06268652Breast Cancer, Refractory Breast Carcinoma
Sun Yat-sen University
Phase 3
302
Guangzhou
2024-01-15
Recruiting
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
NCT06208371Colorectal Neoplasms Malignant
Sun Yat-sen University
Phase 3
117
Guangzhou
2024-01-15
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Recruiting
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
NCT05965531Rectal Cancer
Sun Yat-sen University
Phase 2
65
Guangzhou
2024-01-01
Recruiting
The Cold Ischemia Robot-assisted Partial Nephrectomy
NCT07326280Renal Cell Carcinoma, Renal Function Abnormal
Sun Yat-sen University
Not applicable
310
Guangzhou
2024-01-01
Active, closed
Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study
NCT06881225Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Recruiting
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
NCT05457829Rhabdomyosarcoma, Child
Sun Yat-sen University
Phase 2
88
Guangzhou
2023-12-30
Recruiting
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
NCT06201065Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
200
Guangzhou
2023-12-26
Recruiting
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
NCT06433869Malignant Ascites
Sun Yat-sen University
Phase 2
60
Guangzhou
2023-12-14
Recruiting
SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
NCT06219980SBRT
Sun Yat-sen University
Phase 2
25
Guangzhou
2023-12-07
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
Sun Yat-sen University
Phase 2
71
Guangzhou
2023-12-01
Active, closed
Guangzhou Preterm and Term Birth Cohort Study
NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity
Sun Yat-sen University
Observational
200
Guangzhou
2023-11-21
Recruiting
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
NCT05959356Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
198
Foshan, Guangzhou, Guiyang
2023-11-09
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Not yet open
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
NCT05988372Locally Advanced Pancreatic Cancer
Sun Yat-sen University
Phase 2
50
Guangzhou
2023-10-23
Not yet open
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
Sun Yat-sen University
Phase 2
44
Guangzhou
2023-10-18
Recruiting
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
NCT06092957Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Recruiting
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
NCT05949931Classic Hodgkin Lymphoma
Sun Yat-sen University
Phase 2
108
Guangzhou
2023-10-01
Recruiting
Evaluation of Phacogoniotomy in Medically-controlled POAG
NCT06201455Glaucoma, Open-Angle, Cataract Complicated, Goniotomy
Sun Yat-sen University
Not applicable
100
Guangzhou
2023-09-28
Active, closed
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
NCT05979961Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Active, closed
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT05807880Nasopharyngeal Neoplasms
Sun Yat-sen University
Phase 2
59
Guangzhou
2023-09-01
Recruiting
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
NCT06043999Chemotherapy Effect, Rectal Cancer
Sun Yat-sen University
Not applicable
392
Guangzhou
2023-09-01
Recruiting
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
NCT06031285Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
43
Guangzhou
2023-09-01
Active, closed
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
NCT06020885Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 1
18
Guangzhou
2023-08-31
Recruiting
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
NCT05962502Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
54
Guangzhou
2023-08-24
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
NCT05949944Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 1/2
44
Guangzhou
2023-08-15
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
NCT07003191Type 2 Diabetes
Sun Yat-sen University
Observational
2,600
Guangzhou
2023-08-02
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis
NCT06036862Anastomotic Stenosis
Sun Yat-sen University
Not applicable
50
Guangzhou
2023-08-01
Recruiting
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
NCT06204484Colorectal Cancer
Sun Yat-sen University
Not applicable
349
Guangzhou
2023-07-26
Recruiting
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
NCT05571644Colorectal Cancer
Sun Yat-sen University
Phase 2
143
Guangzhou
2023-07-10
Recruiting
PaCIFiC-CUP Classifies Cancer of Unknown Primary
NCT06140992Unknown Primary Tumors, DNA Methylation
Sun Yat-sen University
Observational
120
Guangzhou
2023-07-01
Recruiting
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
NCT05623267Limited Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2/3
346
Guangzhou
2023-07-01
Rows per page Showing 201–300 of 451
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 451 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

276 of the 451 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 94 have not yet opened recruitment, 73 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.